Differentiated Thyroid Cancer Treatment Pathway Map
Version 2019.09

Disclaimer
The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.
Pathway Map Considerations

- Primary care providers play an important role in the cancer journey and should be informed of relevant tests and consultations. Ongoing care with a primary care provider is assumed to be part of the pathway map. For patients who do not have a primary care provider, Health Care Connect, is a government resource that helps patients find a doctor or nurse practitioner.
- Throughout the pathway map, a shared decision-making model should be implemented to enable and encourage patients to play an active role in the management of their care. For more information see Person-Centered Care Guideline.
- Hyperlinks are used throughout the pathway map to provide information about relevant CCO tools, resources and guidance documents, including documents from CCO’s Evidence-Based Series (EBS).
- The term ‘health care provider’, used throughout the pathway map, includes primary care providers and specialists, nurse practitioners, endocrinologists, and emergency physicians.
- In Ontario, various specialties have taken on an expanded role in the management of differentiated thyroid cancers. Throughout the pathway, specialist referrals imply a physician with specific expertise in that particular aspect of the management of thyroid cancer
- Multidisciplinary Cancer Conferences provide a forum for discussing patients with thyroid cancer about whom there are complexities regarding diagnosis and management. For more information on Multidisciplinary Cancer Conferences visit MCC Tools.
- For more information on wait time prioritization, visit Surgery Wait Time Prioritization.
- Clinical trials should be considered for all phases of the pathway.
- Psychosocial oncology (PSO) is the interprofessional specialty concerned with understanding and treating the social, practical, psychological, emotional, spiritual and functional needs and quality-of-life impact that cancer has on patients and their families. Psychosocial care should be considered an integral and standardized part of cancer care for patients and their families at all stages of the illness trajectory. For more information, visit EBS #19-3.
- The following should be considered when weighing the treatment options described in this pathway map for patients with potentially life-limiting illness:
  - Palliative care may be of benefit at any stage of the cancer journey, and may enhance other types of care – including restorative or rehabilitative care – or may become the total focus care.
  - Ongoing discussions regarding goals of care is central to palliative care, and is an important part of the decision-making process. Goals of care discussions include the type, extent and goal of a treatment or care plan, where care will be provided, which health care providers will provide the care, and the patient’s overall approach to care.
- For more information on the systemic treatment QPB please refer to the Quality-Based Procedures Clinical Handbook for Systemic Treatment.

* Note. EBS#19-3 is older than 3 years and is currently listed as ‘For Education and Information Purposes’. This means that the recommendations will no longer be maintained but may still be useful for academic or other information purposes.

Pathway Map Notes

- Conversion factor for Tg ng/mL to pmol/L: 1 ng/mL Tg = 1.515 pmol/L
- When measuring Thyroglobulin (Tg), include measurement of Thyroglobulin antibodies as well
- Adverse histopathological features: angioinvasion (excluding iatrogenic invasion), tall cell >50%, hobnail cell >30%, columnar cell change in >30% of tumor, solid growth >30%, widely invasive growth, any level of dedifferentiation, strathyroidal psammomatous [Consensus]
- Evidence
- Pathology
- Oncology
- Radiation
- Medical
- Radiology
- Multidisciplinary Cancer Conference (MCC)
- Endocrinology
- Nuclear Medicine
- Psychosocial Oncology

Pathway Map Legend

- Primary Care
- Palliative Care
- Pathology
- Surgery
- Radiation Oncology
- Medical Oncology
- Radiology
- Multidisciplinary Cancer Conference (MCC)
- Endocrinology
- Nuclear Medicine
- Psychosocial Oncology

Pathway Map Disclaimer

This pathway map is a resource that provides an overview of the treatment that an individual in the Ontario cancer system may receive.

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

While care has been taken in the preparation of the information contained in the pathway map, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability. CCO and the pathway map’s content providers (including the physicians who contributed to the information in the pathway map) shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the pathway map or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the pathway map does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the pathway map.

This pathway map may not reflect all the available scientific research and is not intended as an exhaustive resource. CCO and its content providers assume no responsibility for omissions or incomplete information in this pathway map. It is possible that other relevant scientific findings may have been reported since completion of this pathway map. This pathway map may be superseded by an updated pathway map on the same topic.
The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

### Staging of Papillary and Follicular Thyroid Carcinoma

<table>
<thead>
<tr>
<th>Age &lt;55 years old</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>Any T</td>
<td>Any N</td>
<td>M0</td>
</tr>
<tr>
<td>Stage II</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age &gt;55 years old</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>T1a, T1b, T2</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage II</td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage III</td>
<td>T4a</td>
<td>Any N</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVA</td>
<td>T4b</td>
<td>Any N</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVB</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

AJCC Cancer Staging Manual 8th edition
UICC The TNM Classification of Malignant Tumours, 8th Edition
The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

Differentiated Thyroid Cancer Treatment Pathway Map

Low Risk

- Minimally invasive follicular carcinoma
- Non-invasive encapsulated follicular variant of papillary thyroid carcinoma (EFVT) or noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)
- pT1 and any age, or pT2 and <55 years of age
- Microscopic pN1 disease (<2mm with up to 5 nodes)
- No adverse histopathological features

Thyroid Function Tests

2-3 months post-treatment to check adequacy of thyroid hormone replacement therapy

Ultrasound Neck

If post-operative Tg or Tg antibodies elevated

Surveillance

Every 1-2 years for 5 years, then discharge to primary care provider

MCC

Screen for psychosocial needs, and assessment and management of symptoms.

Consider the introduction of palliative care, early and across the cancer journey

Thyroid Hormone Replacement Therapy to Normal Range [Consensus]

Physical Exam

Blood Work

TSH, Serum Tg

Blood Work

TSH, Serum Tg

Ultrasound Neck

If post-operative Tg or Tg antibodies elevated

Some patients may require more frequent follow up, i.e. every 6 months

Physical Exam

Return to primary care provider for follow-up

Progression or Recurrence

Proceed to Page 8

For adverse histopathological features refer to page 2, notes section.

Click here for more information about symptom assessment and management tools

Click here for more information about palliative care
The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

---

**Screen for psychosocial needs, and assessment and management of symptoms.** Click here for more information about symptom assessment and management tools

Consider the introduction of palliative care, early and across the cancer journey Click here for more information about palliative care

---

2 For adverse histopathological features refer to page 3, notes section.
3 Tg level is assay dependent. Classifications may vary by center. [Consensus].
4 Upon careful discussion patient may opt to not receive radioactive iodine, or patient who had hemithyroidectomy only and will therefore not have RAI.
5 Appropriate radiation dose of iodine should be proportional to risk. The high intermediate risk group is heterogeneous, which warrants a broad range of appropriate dosages. 30 mCi may be appropriate for limited adverse histological features.
6 Both the level and duration of TSH suppression is dependent on assessment of potential benefit, patient factors and risks. Initial TSH suppression should be within 0.1-0.5mIU/L for intermediate risk, <0.1mIU/L may be considered for higher risk [Consensus].
7 Recombinant TSH is provincially not funded but can be accessed in place of thyroid hormone withdrawal if patient is insured, over the age of 65, or pays out of pocket. Recombinant TSH should be utilized if possible [Consensus].
8 Recommended: Annual or biannual neck exam, TSH, thyroglobulin, antithyroglobulin, and calcium as indicated. If there is a new lump(s) or swelling in the neck area, persistent neck pain, change in voice or swallowing or rising thyroglobulin, US of neck and referral back to specialist are to be considered.
Differentiated Thyroid Cancer Treatment Pathway Map

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

Screen for psychosocial needs, and assessment and management of symptoms. Click here for more information about symptom assessment and management tools

Consider the introduction of palliative care, early and across the cancer journey Click here for more information about palliative care

---

**Differentiated Thyroid Cancer Treatment Pathway Map**

1. From page 4, if the path is High Risk: Gross extrathyroidal extension with no macroscopic residual disease, refer to the Surgeon with appropriate expertise.
2. If not resectable, refer to the Nuclear Medicine.
3. If resectable, refer to the Radiation Oncologist.
4. If no residual disease, refer to the Endocrinologist or Nuclear Medicine.
5. If residual disease, refer to the External Beam Radiation Therapy (EBRT) to neck.
6. Post-Treatment Radioiodine Imaging.
7. Baseline CT Neck Thorax if not previously done.
8. Post-Treatment Radioiodine Therapy (3-5 years).
9. TSH Suppression Therapy (3-5 years).
10. Physical Exam, Blood Work, TSH, FT4, Serum Tg, TSH-stimulated Tg or High sensitivity Tg assay.
11. Ultrasound Neck if post-operative Tg or Tg antibodies elevated.
12. Diagnostic Whole Body RAI Scan (following thyroid hormone withdrawal OR TSH)(3).
13. PET-CT if patient has elevated serum Tg (>10 ng/ml) and any negative imaging.
14. CT Neck Thorax if previously positive.
15. If CT is positive, consider further radioactive iodine (150 - 200mCi)(2).
16. Annual surveillance for 10 years, then discharge to primary care provider.
17. Return to primary care provider for follow-up.
18. Progression to Page 8.
20. From Page 9, if not previously done, refer to the Physical Exam.
22. Basal Serum Tg Measured on Thyroid Hormone Suppression Therapy.
23. Ultrasound Neck.
24. Progression to Page 10.
25. If post, return to primary care provider.

---

**Notes:**

- Version 2019.09 Page 7 of 11
- The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map.
- The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.
- Consider the introduction of palliative care, early and across the cancer journey.
- Screen for psychosocial needs, and assessment and management of symptoms.

---

**References:**

1. Both the length and duration of TSH suppression is dependent on assessment of potential benefit, patient factors and risks. Initial TSH suppression should be within 0.1-0.5mIU/L for intermediate risk, >0.1mIU/L may be considered for higher risk [Consensus].
2. Recombinant TSH is provincially not funded but may have been performed in the place of thyroid hormone withdrawal if patient is insured, is over the age of 65, or patient paid out of pocket. Recombinant TSH should be utilized if possible [Consensus].
3. Recommended. Annual or biennial neck exam, TSH, thyroglobulin, antithyroglobulin, and calcium. If there is a new lump(s) or swelling in the neck area, persistent neck pain, change in voice or swallowing or rising thyroglobulin, US of neck and referral back to specialist are to be considered.
4. In presence of lung metastases, consider age, number of lesions, and risk for fibrosis when determining RAI dosage. Avoid >150mCi for over patients over 70 (EBT 5-13); a dosage of 150mCi should be considered for older patients and those with higher risk of fibrosis, and a dosage of 200mCi should be considered for young, healthy patients with a greater number of lesions. Qualify with a glomerular filtration rate (GFR) Test [Consensus].
5. Patient receiving EBRT should be referred to a Registered Dietitian and Speech Language Pathologist.
Differentiated Thyroid Cancer Treatment Pathway Map

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

Screen for psychosocial needs, and assessment and management of symptoms. Click here for more information about symptom assessment and management tools

Consider the introduction of palliative care, early and across the cancer journey Click here for more information about palliative care

---

**Recurrent Disease or Progression**

---

**Pathway Map**

---

**Recommendations**

9 Recommend: Annual or biennial neck exam, TSH, thyroglobulin, antithyroglobulin, and calcium. If there is a new lump(s) or swelling in the neck area, persistent neck pain, change in voice or swallowing or rising thyroglobulin, US of neck and referral back to specialist are to be considered.

10 Suspicious features that warrant nodal biopsy:
- On ultrasound: rounded shape, hypoechoic, cystic, small foci of calcification, or central necrosis
- On CT: rounded shape, enhancement, cystic, small foci of calcification, or central necrosis

- Size: size is only of consideration if there are suspicious features present, there is no need to biopsy on size alone. In presence of suspicious features, biopsy is recommended if the shortest dimension in the axial plane is >8mm.

11 Indications for PET Scan include: recurrent or persistent disease suspected on the basis of an elevated and/or rising thyroglobulin level(s) but standard imaging studies, including I-131 scan and/or neck ultrasound, are negative or equivocal.
Screen for psychosocial needs, and assessment and management of symptoms. [Click here for more information about symptom assessment and management tools]

Consider the introduction of palliative care, early and across the cancer journey [Click here for more information about palliative care]

---

**Differentiated Thyroid Cancer Treatment Pathway Map**

**Recurrent Disease or Progression (Cont'd)**

- **Resected**?
  - Resected
  - Unresected

**Avid?**
- Avid
  - Consider aggressive local therapies for oligometastatic disease:
    - Surgery
    - EBRT
    - Post-Treatment Radioiodine Imaging

**Non-avid, or avid disease that is progressing**
- Prepare for Radiative Iodine (EBS 5-13)
- Proceed as appropriate

**Further Progression**
- Follow-Up as appropriate
- Consider if further progression or poor response:
  - Medical Oncologist
  - Systemic Therapy

**Post-Treatment Radioiodine Imaging**
- Appropriate therapy may include one or more of the following:
  - EBRT
  - Systemic Therapy
  - Psychosocial Oncology & Palliative Care

**Preparation for Radiative Iodine (EBS 5-13)**
- Radiative Iodine (150-200mCi)
- Post-Treatment Radioiodine Imaging

**External Beam Radiation Therapy (EBRT)**
- Radiologist
- Endocrinologist
- Nuclear Medicine

---

10 In presence of lung metastases, consider age, number of lesions, and risk for fibrosis when determining RAI dosage. Avoid >150mCi for over patients over 70 [EBS 5-13]: a dosage of 150mCi should be considered for older patients and those with higher risk of fibrosis, and a dosage of 200mCi should be considered for young, healthy patients with a greater number of lesions. Qualify with a glomular filtration rate (GFR) test [Consensus].

11 Patient receiving external beam radiation therapy (EBRT) should be referred to a Registered Dietitian and Speech Language Pathologist.
Differentiated Thyroid Cancer Treatment Pathway Map

The pathway map is intended for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

**End of Life Care**

- **Revisit Advance Care Planning**
  - Ensure the patient has determined who will be their Substitute Decision Maker (SDM)
  - Ensure the patient has communicated to the SDM his/her wishes, values and beliefs to help guide that SDM in future decision making

- **Discuss and document goals of care with patient and family**
  - Assess and address patient and family’s information needs and understanding of the disease, address gaps between reality and expectation, foster realistic hope and provide opportunity to explore prognosis and life expectancy, and preparedness for death
  - Introduce patient and family to resources in community (e.g., day hospice programs)

- **Develop a plan of treatment and obtain consent**
  - Determine who the person wants to include in the decision making process (e.g., substitute decision maker if the person is incapable)
  - Develop a plan of treatment related to disease management that takes into account the person’s values and mutually determined goals of care
  - Obtain consent from the capable person or the substitute decision maker if the person is incapable for an end-of-life plan of treatment that includes:
    - Setting for care
    - Resuscitation status
    - Having, withholding and or withdrawing treatments (e.g. lab tests, medications, etc.)

- **Screen for specific end of life psychosocial issues**
  - Specific examples of psychological needs include: anticipatory grief, past trauma or losses, preparing children (young children, adolescents, young adults), guardianship of children, death anxiety
  - Consider referral to available resources and/or specialized services

- **Identify patients who could benefit from specialized palliative care services (consultation or transfer)**
  - Discuss referral with patients and family

- **Proactively develop and implement a plan for expected death**
  - Explore place-of-death preferences and assess whether this is realistic
  - Explore the potential settings of dying and the resources required (e.g., home, residential hospice, palliative care unit, long term care or nursing home)
  - Anticipate/Plan for pain & symptom management medications and consider a Symptom Response Kit (SRK) for unexpected pain & symptom management
  - Preparation and support for family to manage
  - Discuss emergency plans with patient and family (who to call if emergency in the home or long-term-care or retirement home)

- **Home care planning**
  - Connect with CCAC early (not just for last 2-4 weeks)
  - Ensure resources and elements in place
  - Consider a Symptom Response Kit (SRK) with access to pain, dyspnea and delirium medication
  - Identify family members at risk for abnormal/complicated grieving and connect them proactively with bereavement resources

---

**Triggers that suggest patients are nearing the last few months and weeks life**

- ECOG/Patient-ECOG/PRFS = 4 OR PPS ≤ 30
- Declining performance status/functional ability
- Gold Standards Framework indicators of high mortality risk

---

**Screen, Assess, Plan, Manage and Follow-Up**

- End of Life Care planning and implementation
- Collaboration and consultation between specialist-level care teams and primary care teams

---

**Pathway Map Target Population:** Individuals with cancer approaching end of life, and their families.

While this section of the pathway map is focused on the care delivered at the end of life, the palliative care approach begins much earlier on in the illness trajectory. Refer to [Screen, Assess & Plan within the Psychosocial & Palliative Care Pathway Map](#).
**At the time of death:**
- Pronouncement of death
- Completion of death certificate
- Allow family members to spend time with loved one upon death, in such a way that respects individual rituals, cultural diversity and meaning of life and death
- Implement the pre-determined plan for expected death
- Arrange time with the family for a follow-up call or visit
- Provide age-specific bereavement services and resources
- Inform family of grief and bereavement resources/services
- Initiate grief care for family members at risk for complicated grief
- Encourage the bereaved to make an appointment with an appropriate health care provider as required

**Bereavement Support and Follow-Up**
- Offer psychoeducation and/or counseling to the bereaved
- Screen for complicated and abnormal grief (family members, including children)
- Consider referral of bereaved family member(s) and children to appropriate local resources, spiritual advisor, grief counselor, hospice and other volunteer programs depending on severity of grief

Provide opportunities for debriefing of care team, including volunteers